Til patienter med risiko for akut nyresvigt eller tromboemboliske episoder bør IVIg- præparater indgives med den lavest mulige infusionshastighed og dosis.
In patients at risk for acute renal failure or thromboembolic adverse reactions, IVIg products should be administered at the minimum rate of infusion and dose practicable.